These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 16998501)

  • 21. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.
    Fridlich R; Annamalai D; Roy R; Bernheim G; Powell SN
    DNA Repair (Amst); 2015 Jun; 30():11-20. PubMed ID: 25836596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
    Liu G; Yang D; Sun Y; Shmulevich I; Xue F; Sood AK; Zhang W
    Pharmacogenomics; 2012 Oct; 13(13):1523-35. PubMed ID: 23057551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
    Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
    Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
    Barwell J; Pangon L; Georgiou A; Kesterton I; Langman C; Arden-Jones A; Bancroft E; Salmon A; Locke I; Kote-Jarai Z; Morris JR; Solomon E; Berg J; Docherty Z; Camplejohn R; Eeles R; Hodgson SV
    Int J Cancer; 2007 Oct; 121(7):1631-6. PubMed ID: 17582599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.
    Gudmundsdottir K; Lord CJ; Witt E; Tutt AN; Ashworth A
    EMBO Rep; 2004 Oct; 5(10):989-93. PubMed ID: 15359272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
    Bhattacharyya A; Ear US; Koller BH; Weichselbaum RR; Bishop DK
    J Biol Chem; 2000 Aug; 275(31):23899-903. PubMed ID: 10843985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
    Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
    Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic steps of mammalian homologous repair with distinct mutagenic consequences.
    Stark JM; Pierce AJ; Oh J; Pastink A; Jasin M
    Mol Cell Biol; 2004 Nov; 24(21):9305-16. PubMed ID: 15485900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.
    O'Donovan PJ; Livingston DM
    Carcinogenesis; 2010 Jun; 31(6):961-7. PubMed ID: 20400477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAD51 localization and activation following DNA damage.
    Tarsounas M; Davies AA; West SC
    Philos Trans R Soc Lond B Biol Sci; 2004 Jan; 359(1441):87-93. PubMed ID: 15065660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human syndromes with genomic instability and multiprotein machines that repair DNA double-strand breaks.
    De la Torre C; Pincheira J; López-Sáez JF
    Histol Histopathol; 2003 Jan; 18(1):225-43. PubMed ID: 12507302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
    Wang W; Figg WD
    Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
    Chalasani P; Livingston R
    Oncologist; 2013; 18(8):909-16. PubMed ID: 23881989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
    Sy SM; Huen MS; Chen J
    Proc Natl Acad Sci U S A; 2009 Apr; 106(17):7155-60. PubMed ID: 19369211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
    Ohashi A; Zdzienicka MZ; Chen J; Couch FJ
    J Biol Chem; 2005 Apr; 280(15):14877-83. PubMed ID: 15671039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
    Honrado E; Osorio A; Palacios J; Milne RL; Sánchez L; Díez O; Cazorla A; Syrjakoski K; Huntsman D; Heikkilä P; Lerma E; Kallioniemi A; Rivas C; Foulkes WD; Nevanlinna H; Benítez J
    J Clin Oncol; 2005 Oct; 23(30):7503-11. PubMed ID: 16234517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2.
    Foray N; Randrianarison V; Marot D; Perricaudet M; Lenoir G; Feunteun J
    Oncogene; 1999 Dec; 18(51):7334-42. PubMed ID: 10602489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
    Zhang F; Fan Q; Ren K; Andreassen PR
    Mol Cancer Res; 2009 Jul; 7(7):1110-8. PubMed ID: 19584259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.